During a live event, Hannah Choe, MD, analyzed key findings from the AGAVE-201 trial of axatilimab in chronic graft-vs-host disease. A significant number of patients who develop chronic graft-vs-host ...

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

Special Report: Entropy Neurodynamics has completed dosing of its IV-infused psilocin TRP-8803 for the first patient ...

Baxter International Inc. BAX recently shared real-world data at the American Society of Health-System Pharmacists (“ASHP”) ...

The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute –– Availability of Lunsumio VELO allows ...

Every day, children are facing long treatments at Albany Medical Center’s infusion and apheresis centers, where they are sometimes spending hours in a hospital bed, hooked up to IV medications.One of ...

With all the buzzwords surrounding artificial intelligence, from smiling promotions to angry chagrins—promises that it will ...

This article is based on TheStreet’s Stock & Markets Podcast. Hosted by Chris Versace, the veteran Wall Street investor and ...

Treatment with Kisunla was associated with sustained clinical benefits, specifically less symptom worsening and significant ...

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company is spearheading a ...